Methods and results
MYOCARDIAL INFARCTION
EMMACE is a linked multicentre prospective cohort study of 14 899 patients with MI
admitted to 77 hospitals in England who participated in the EMMACE-3 and -4 studies
between 1st November 2011 and 24th June 2015. Long-term follow-up of the EMMACE cohorts
was conducted through the EMMACE-XL (27th September 2020 to 31st March 2022) and
EMMACE-XXL (1st July 2021 to 1st July 2023) studies. EMMACE collected individual
participant data for health-related quality of life (HRQoL) measured by three-level
EuroQol five-dimension and visual analogy scale at admission, 1 month, 6 months, 12
months, and 10 years follow-up, as well as medications, medication adherence, beliefs
about medicines, Satisfaction with Information about Medicines Scale, and illness
perceptions. Participant data were deterministically linked to the Myocardial Infarction
National Audit Project (MINAP) for information on baseline treatments and comorbidities,
Hospital Episode Statistics Admitted Patient Care (for cause-specific hospitalization
data), and the Office for National Statistics (for mortality data) up to 2020.